Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind Placebo-Controlled Atogepant in Pediatric Episodic Migraine
jRCT2051230212Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in episodic migraine comparing Atogepant with Placebo (2 arms). Primary endpoint: Change from Baseline in Mean Monthly Migraine Days. Started Mar 2024; status: recruiting.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on jRCT2051230212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230212.